Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Autologous T-cells Redirected to Mesothelin With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer

NCT03638193 is registered in ClinicalTrials.gov with Shenzhen BinDeBio Ltd. as lead sponsor.

NCT NCT03638193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03638193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Autologous T-cells Redirected to Mesothelin With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Shenzhen BinDeBio Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
July 11, 2018
Completion date
February 1, 2022
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer